Navigation Links
Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
Date:8/19/2007

- Ardea Biosciences Receives Milestone Payment from Valeant Pharmaceuticals

-

CARLSBAD, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Pink Sheets: ARDC) today announced that it has received the first milestone payment of $0.5 million from its collaboration partner, Valeant Pharmaceuticals International (NYSE: VRX).

In December 2006, Ardea Biosciences entered into a research collaboration with Valeant Pharmaceuticals International pursuant to which we agreed to collaborate exclusively with Valeant to design a series of compounds to treat neurological disorders.

Valeant's announcement of the selection of several pre-Investigational New Drug (IND) candidates for its next-generation potassium-channel opener program triggered this milestone payment, which recognizes the continuing progress in the identification of novel next-generation compounds to treat serious diseases.

"Starting with a very interesting first generation compound, we have successfully improved its metabolic and pharmacokinetic properties, while increasing potency by up to 50-fold. We are pleased to be recognized for achieving this important milestone and for its validation of our fully-integrated discovery, research and development platform," said Barry D. Quart, PharmD, President and CEO.

About Ardea Biosciences, Inc.

Ardea is focused on the development of small-molecule drugs that address large pharmaceutical markets. We plan to source these development candidates from both our internal drug discovery programs and our continued in-licensing efforts. Our initial therapeutic areas of focus are viral diseases, cancer and inflammatory diseases. We believe that we are well-positioned to create shareholder value through our development activities given our ability to achieve clinical proof-of-concept relatively quickly and cost-effectively in these disease areas. The Company's goal is to initiate clinical studies on three or more compounds this year. These compounds include RDEA806 and lead compounds from our 900 series, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV, and RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, its plan to source development candidates, and its goal of initiating clinical studies on three or more compounds this year. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Plasmid Miniprep Kit Selection
3. Selection of Standards for Bio-Plex Cytokine Assays, Rev A
4. Tired of the spin? ExpertVoter website makes candidate selection easier
5. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
6. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
7. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
8. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
9. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
10. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, ... by the Parenteral Drug Association (PDA), the New York Interphex Show will open on ... and more than 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... biotech companies, recently announced it will debut a brand new pressure vessel, the ... intelliVessel is controlled by a touch screen panel and features other revolutionary operations ...
(Date:3/20/2017)... Yorba Linda, CA (PRWEB) , ... March 20, ... ... interference and require expensive and laborious sample preparation methods in order to reduce ... is often underappreciated outside of the area of elemental analysis. , This ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
Breaking Biology Technology:
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):